Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00939796 · ClinicalTrials.gov registry record · NA

Clinical Study of the Tympanostomy Tube Delivery System

A NA study, sponsored by Integra LifeSciences Corporation.

Completed
Registry status
NA
Development phase
16
Enrollment target

NCT00939796: Completed NA study, sponsored by Integra LifeSciences Corporation.

NCT00939796 is a NA study that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00939796, a NA study, has completed, sponsored by Integra LifeSciences Corporation.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target

Study Summary

The objective of this investigational study is to evaluate the safety and performance of the Acclarent Tympanostomy Tube Delivery System (TTDS) for the placement of the Tympanostomy Tube \[TT(s)\] in patients indicated for such treatment for chronic otitis media with effusion (OME) or recurrent acute otitis media (AOM).

Primary Outcome

Successful deployment of the tube in each indicated ear using the TTDS. Evaluated for test cohort subjects only (not lead-in subjects).

Interventions

  • DEVICE Acclarent Tympanostomy Tube Delivery System

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2009-03
Est. Completion 2009-07
Phase NA
Integra LifeSciences Corporation

60 total trials

What the finished NCT00939796 record still lists

NCT00939796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Acclarent Tympanostomy Tube Delivery System is the first listed.

NCT00939796 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00939796 about?

NCT00939796 is a clinical study titled "Clinical Study of the Tympanostomy Tube Delivery System". The objective of this investigational study is to evaluate the safety and performance of the Acclarent Tympanostomy Tube Delivery System (TTDS) for the placement of the Tympanostomy Tube \[TT(s)\] in patients indicated for such treatment for chronic otitis media with effusion (OME) or recurrent acut...

What is the current status of trial NCT00939796?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2009-03. Estimated completion is 2009-07.

What interventions are being tested in trial NCT00939796?

The interventions under investigation include: Acclarent Tympanostomy Tube Delivery System (DEVICE).

Who is sponsoring clinical trial NCT00939796?

This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00939796's enrollment target sits among peer trials

16 1871st of 2000 higher than 120 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00939796, the US trial registry maintained by the National Library of Medicine. NCT00939796 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.